Concentric Medical Completes TREVO Enrollment

September 8, 2011—Concentric Medical, Inc. (Mountain View, CA) announced completion of enrollment in the TREVO (Thrombectomy Revascularization of Large Vessel Occlusions in Acute Ischemic Stroke) study. The study is a European, multicenter, prospective clinical trial evaluating the company's Stentriever technology in its latest generation of the Trevo thrombus retrieval system. The TREVO study was designed to assess the ability of the Trevo system to remove blood clots that cause strokes and to restore blood flow to the brain. Prof. Olav Jansen, MD, and Prof. Nils Wahlgren, MD, are Coprincipal Investigators of the study.

According to the company, Prof. Jansen presented interim data from the study at the European Stroke Congress in May 2011. The interim revascularization rate in the first 36 patients was 96%. Thirty patients had 90-day follow-up, and 63% of these patients had a favorable outcome. A favorable outcome was defined as patients being functionally independent at 90 days (modified Rankin score of 2 or less).

Prof. Wahlgren commented, “The TREVO study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo system. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes for these patients.”

Juan Macho, MD, added, “The Trevo system is the first device of this type designed specifically for removal of the clot in ischemic stroke patients. Not only was it easy to use, but the architectural properties of the device enhance clot integration into the device, making the procedures fast and remarkably effective.”